12/1
07:20 am
huma
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Medium
Report
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at UBS Group AG.
12/1
07:20 am
huma
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/27
06:40 pm
huma
Humacyte (HUMA) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Humacyte (HUMA) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
11/21
08:05 am
huma
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $6.00 price target on the stock.
Medium
Report
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $6.00 price target on the stock.
11/20
09:46 am
huma
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Medium
Report
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
11/20
08:00 am
huma
Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results
Medium
Report
Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results
11/13
01:39 pm
huma
Humacyte (NASDAQ:HUMA) had its price target lowered by analysts at Benchmark Co. from $14.00 to $11.00. They now have a "buy" rating on the stock.
Low
Report
Humacyte (NASDAQ:HUMA) had its price target lowered by analysts at Benchmark Co. from $14.00 to $11.00. They now have a "buy" rating on the stock.
11/13
08:38 am
huma
Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium) [Yahoo! Finance]
Medium
Report
Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium) [Yahoo! Finance]
11/13
08:00 am
huma
Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)
Medium
Report
Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)
11/12
03:02 pm
huma
Humacyte Inc (HUMA) Q3 2025 Earnings Call Highlights: Strong Symvess Sales Growth Amidst ... [Yahoo! Finance]
Low
Report
Humacyte Inc (HUMA) Q3 2025 Earnings Call Highlights: Strong Symvess Sales Growth Amidst ... [Yahoo! Finance]
11/12
12:27 pm
huma
Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/12
12:23 pm
huma
Humacyte outlines 12-month cash runway and accelerates Symvess adoption following $56.5M capital raise [Seeking Alpha]
Low
Report
Humacyte outlines 12-month cash runway and accelerates Symvess adoption following $56.5M capital raise [Seeking Alpha]
11/12
07:54 am
huma
Humacyte GAAP EPS of -$0.11 beats by $0.05, revenue of $0.75M misses by $0.17M [Seeking Alpha]
High
Report
Humacyte GAAP EPS of -$0.11 beats by $0.05, revenue of $0.75M misses by $0.17M [Seeking Alpha]
11/12
07:00 am
huma
Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update
11/11
08:22 am
huma
Earnings To Watch: Humacyte Inc (HUMA) Reports Q3 2025 Result [Yahoo! Finance]
Medium
Report
Earnings To Watch: Humacyte Inc (HUMA) Reports Q3 2025 Result [Yahoo! Finance]
11/10
01:48 pm
huma
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Neutral
Report
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
11/10
08:40 am
huma
Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025 [Yahoo! Finance]
Medium
Report
Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025 [Yahoo! Finance]
11/10
08:00 am
huma
Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology’s Kidney Week 2025
Medium
Report
Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology’s Kidney Week 2025
11/6
08:00 am
huma
Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025
High
Report
Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025
10/30
08:12 pm
huma
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know [Yahoo! Finance]
Low
Report
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know [Yahoo! Finance]
10/30
08:00 am
huma
Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma
Medium
Report
Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma
10/17
07:50 pm
huma
Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why [Yahoo! Finance]
Medium
Report
Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why [Yahoo! Finance]
10/13
12:11 pm
huma
Humacyte (NASDAQ:HUMA) was given a new $6.00 price target on by analysts at UBS Group AG.
Medium
Report
Humacyte (NASDAQ:HUMA) was given a new $6.00 price target on by analysts at UBS Group AG.
10/13
08:07 am
huma
Humacyte (NASDAQ:HUMA) had its price target lowered by analysts at BTIG Research from $7.00 to $6.00. They now have a "buy" rating on the stock.
High
Report
Humacyte (NASDAQ:HUMA) had its price target lowered by analysts at BTIG Research from $7.00 to $6.00. They now have a "buy" rating on the stock.
10/12
02:19 am
huma
Humacyte (HUMA) Is Down 25.7% After Reporting Strong Symvess Trauma Results and Completing $60M Equity Raise [Yahoo! Finance]
High
Report
Humacyte (HUMA) Is Down 25.7% After Reporting Strong Symvess Trauma Results and Completing $60M Equity Raise [Yahoo! Finance]